Mountain View, CA – February 3, 2012: VIDA Diagnostics, Inc. today announced the opening of a new branch office in Mountain View, CA in Silicon Valley as part of the company's initiative to develop key growth markets and support its global commercialization strategy.
Read Press Release>>
Funding Will Support Commercialization of InterVapor for Treatment of Severe Emphysema
TUSTIN, Calif., Jan. 9, 2012 – Uptake Medical® today announced that it has closed on a Series C funding round. The round was led by Singapore-based Crescent Point Group, with existing investors, Maverick Capital, ONSET Ventures, GBS Venture Partners, WRF Capital, ...
Read Press Release>>
TUSTIN, Calif., Dec. 21, 2011 – Uptake Medical® today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor™ System for endoscopic lung volume reduction for the treatment of severe emphysema.
Read Press Release>>
VIDA® Diagnostics' quantitative pulmonary imaging software, Apollo®, was recently installed at the University of Florence, Italy, for usage in clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes.
The cover of the Pulmão RJ features an image from VIDA's proprietary quanititative imaging software, Apollo. The corresponding journal article, "Tratamento endoscópico do enfisema (Bronchoscopic treatment of emphysema)" and its translation can be reviewed on VIDA's Clinical Validation/Peer Reviewed Literature page here >>
Coralville, IA – September 19, 2011 - VIDA Diagnostics, a leading developer of quantitative pulmonary imaging software, announced today that the company has achieved International Organization for Standardization (ISO 13485) certification and CE certification for its flagship product, Apollo®. The CE certification permits VIDA to sell Apollo for clinical use in the European Economic Area (EEA) and Switzerland. Apollo currently has FDA 510(k) approval for clinical use in the U.S.
VIDA's corporate partner, Uptake Medical, begins clinical procedures in Europe.
Uptake Medical Announces First Commerical Use of InterVapor for Patients with Severe Emphysema. New treatment provides clinically meaningful improvements in lung function and quality of life.
Read Press Release >>
RECENT NEWS/ANNOUNCEMENTS· ALung poised for sales in Germany
· VIDA Diagnostics Opens First Branch Office in Silicon Valley
· The Future of InterVapor: Q&A with Uptake's Chief Medical Officer Steven Kesten
· VIDA Diagnostics Earns ISO 13485 and CE Certifications
· Uptake Medical Announces Successful Completion of Series C Financing
· VIDA® Diagnostics' Software, Apollo®, Installed at U of Florence (Italy)
· Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema
EVENTS CALENDAR
JSPFI 2012 ● The 4th Meeting of the Japanese Society of Pulmonary Functional Imaging
February 10-11, 2012
Otsu City, Japan
ATS 2012 ● The Annual International Conference of the American Thoracic Society.
May 18-23. San Francisco, CA
VIDA Diagnostics is a leader in clinically-validated quantitative pulmonary analysis software for the early detection, evaluation and aiding of treatment of pulmonary disease including COPD, emphysema, lung cancer, and asthma. FDA approved and CE certified, VIDA's analysis methodology has been successfully tested in multiple academic, pulmonary device, and pharmaceutical clinical trials.